📰 Recommended Phase News
Page 6 - Recommended Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recommended Phase. Real-time updates on events, politics, business and more.
April 25, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are...
April 12, 2022
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are...
April 8, 2022
08.04.2022 - Poster presentation highlights translational work supporting recommended dosing for SRF388 Phase 2 trialsCAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) - Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing ... Seite 1
April 4, 2022
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
March 25, 2022
– Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine...
March 23, 2022
Investegate announcements from https://immatics.com/, Immatics Announces Full Year 2021 Financial Results and Corporate Update
March 23, 2022
IMA203 TCR-T candidate targeting PRAME demonstrated a 50% objective response rate across different solid tumor types in an interim update of Phase 1a dose escalationMultiple IMA203 Phase
February 25, 2022
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
February 24, 2022
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...
February 14, 2022
/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...